Bone mineral density, body composition, and mineral homeostasis over 24 months in urban South African women with HIV exposed to antiretroviral therapy Running title (40 characters): aBMD differences in HIV over 2 years.
INTRODUCTION
Despite the ongoing high burden of HIV in Sub-Saharan Africa, the availability of effective combination antiretroviral therapy (ART) has resulted in dramatic survival gains [1] , which are anticipated to continue [2] . With improved survival there has been a greater focus on HIV as a chronic disease of ageing and on HIV-associated non-communicable diseases including bone loss and fractures [3] . While data on female participants [4] [5] [6] [7] [8] have started to emerge from resource-limited settings where osteoporotic fractures are predicted to increase [9] , most studies to date have predominantly been from high-income settings and focused on males, who generally have the lowest lifetime risk of fragility fracture.
There remains uncertainty about the underlying mechanisms and the relative contributions of HIV-infection, ART and lifestyle factors on bone mineral loss. However, the balance of evidence suggests that ART-exposure is a leading contributor [10, 11] . Studies have demonstrated a 2% to 6% reduction in areal bone mineral density (aBMD) following initiation of ART, occurring generally over the first 2 years. Most published studies, from high income countries, report no further reduction in aBMD after 2 years [12] [13] [14] . In an early seminal meta-analysis [12] people with HIV (PWH) were three times more likely to have low areal bone mineral density (aBMD) than controls. In a 2018 meta-analysis PWH and ARTexposed had an odds ratio (OR) of osteoporosis/osteopenia of 2.8 and 3.4 at the lumbar spine and total hip compared to PWH but ART-naïve [15] .The ART agent tenofovir disoproxil fumarate (TDF) is particularly associated with bone loss both in people with [12, 16, 17] and without HIV [18] . The underlying mechanism has not been firmly established and diverse This article is protected by copyright. All rights reserved.
explanations have been proffered including renal phosphate loss, immune reconstitution, inadequate vitamin D status and consequences of macrophage activation [19] [20] [21] .
We have previously demonstrated in a cross-sectional analysis of a cohort of urban, premenopausal South African women, comparing PWH but ART-naïve with those who were HIV-negative, that there were no significant differences in aBMD related to HIV-status. This was despite women with HIV with low CD4 counts being less adipose than those with preserved CD4 counts or HIV-negative women [4] . In a follow up study at 12 months [5] there were significant decreases in aBMD despite significant increases in weight and fat mass. These effects were associated with increased bone turnover markers but there were no differences or changes in vitamin D status, serum phosphate concentration, or renal phosphate handling [5] .
We hypothesized that these African women with HIV and ART-exposed would continue to lose bone mineral after 12 months of therapy. The aim of the study presented in this paper was to follow this cohort of women to 24 months, in order to investigate the effects of continued HIV-infection and ART-exposure on bone mineral density and to consider the influence of potential modulators by measuring body composition, vitamin D status and markers of mineral metabolism and inflammation.
PARTICIPANTS AND METHODS

Study design
The study was designed as a 24-month longitudinal investigation of urban, black South African premenopausal women with and without HIV-infection. Participants attended for study visits between February and July at the SAMRC/Wits Developmental Pathways for Health Research Unit (DPHRU) in Soweto, Johannesburg, SA, at baseline and at 12-and 24months post-baseline. At each visit anthropometry and DXA scans were performed, and biological samples collected. This report focuses on those participants who attended at all three time points and whose data were not excluded because of an intervening pregnancy/lactation or, in the case of the HIV-negative women, seroconversion.
Details of the study protocol, inclusion and exclusion criteria, baseline characteristics and changes to 12 months have been described in full elsewhere [4, 5, 22] . Briefly, 247 women were recruited into three groups of approximately equal size from clinics in Soweto, Johannesburg, between February and July 2010. All were premenopausal and not pregnant/lactating at the time of enrolment. The groups at recruitment were: (i). Women without HIV to serve as the reference group (Negative-reference: Nref, n = 98); (ii). Women with HIV and preserved CD4 counts (≥ 350 x 10 6 cells/l) and anticipated not to require ARTinitiation for at least 12 months (Positive-preserved: Ppres, n = 74) and (iii). Women with HIV and low CD4 counts (≤200 x 10 6 cells/l) eligible to commence ART (Positive-low: Plow n = 75). The criteria used for commencing ART where those in place nationally at the time of commencement of the study. At the 12 and 24-month visits, Nref participants were offered repeat HIV-antibody testing using the Alere Determine™ rapid HIV-antibody test (Alere San Diego, Inc. San Diego, CA, USA). Those who had a reactive HIV test were referred to a local Primary Health Care Facility for confirmatory testing, CD4 count and consideration of ART aBMD loss in excess of the least significant change was determined using the conventional DXA 0.03 g/cm 2 threshold, which is based on a notional instrument precision of 1% [23] .
Laboratory measures
Full details of the blood and urine collection, processing and analytical procedures, including assay and manufacturer information are described in detail elsewhere [4, 5] . In brief, blood was collected in the morning after an overnight fast and processed as EDTA plasma for parathyroid hormone (PTH) analysis and as serum for other analytes relating to calcium, phosphorus and vitamin D metabolism (calcium, phosphate, magnesium, albumin, 25(OH)D), bone turnover (total alkaline phosphatase (TALP); serum type 1 procollagen Nterminal (P1NP); and serum collagen type 1 cross-linked β-C-telopeptide (β-CTX), and This article is protected by copyright. All rights reserved.
inflammation (c-reactive protein (CRP), ferritin). All plasma and serum samples were stored frozen, initially at -20 o C and subsequently at -80 o C. Urine was collected into a sterile container at the second void of the day after an overnight fast, acidified 10 µl/ml with concentrated hydrochloric acid and stored at -20 o C (see supplementary data for full description).
Statistical methods
Data were analyzed using DataDesk 6.3.1 (Data Description Inc, Ithaca, NY). Summary statistics are presented as mean ± standard deviation (SD) for normally distributed data or median [25th percentile, 75th percentile (IQR)] for skewed distributions. Based on findings from the baseline study, fat mass-to-lean mass 2 (fat:lean 2 ) was used to describe body composition [4] . All continuous variables were transformed to natural logarithms prior to data analysis allowing differences between groups and between timepoints to be expressed as sympercents ([difference/mean] x 100) [24] and, for positively skewed distributions to be normalized. Summary sympercent data are presented as percentage mean difference ± SE.
Full details of the statistical approach have been described previously [5] . Group and timepoint differences were investigated using ANOVA, utilizing the Linear Model software in DataDesk with Scheffé post hoc tests. Repeat-measures hierarchical models were constructed to evaluate and compare the within-individual changes in each variable over time between the 3 groups. The results of two models are presented: (a) 2-timepoint analysis (12/24 months) to focus on changes after 12 months (b) 3-timepoint analysis (0/12/24 months) to consider whether the changes associated with ART initiation were also seen in this sub-set of the original cohort. In addition to timepoint, these models included individual identifier (nested by group), group (Nref/ART-N/ART-Y) and a group-by-timepoint interaction term. The bone data were also modelled with BA and body weight as explanatory variables, to adjust for changes in bone and body size [5, 25] . No additional adjustment for covariates such as lifestyle factors was made, because they did not differ significantly between the groups [5] .
RESULTS
The progress of participants through the study and the reasons for loss-to-follow up are detailed in Table 1 details the aBMD, anthropometry and body composition of the three groups at 12 months and 24 months and describes, for each variable, the statistical significance from the 2timepoint model of the between-group differences at each timepoint, the within-individual changes in each group between 12 and 24 months, and the group-by-timepoint interaction terms that indicate whether the time effects differed significantly between groups. The percentage differences in these variables from Nref at 12 and 24 months for ART-N and ART-Y are in Table 2 . To place these results in context with the changes that occurred in the first 12 months, Figure 2 illustrates the percentage differences in aBMD, BMI and fat/lean 2 in each group at 0, 12 months and 24 months expressed relative to Nref at baseline. The summary data, changes from baseline and differences from Nref at baseline, 12 and 24 months are given in Supplementary Tables 1-3 .
The mean ages at baseline were Nref = 32.8±8.8 years, ART-N = 33.9±6.0 years and ART-Y 35.0±5.4 years (P=0.38) and there was no difference in height between the groups. In line with the analysis of the larger cohort followed to 12 months [5] , there were no significant differences in cross-sectional tests between the groups at baseline in aBMD at any of the four skeletal sites, although the longitudinal models indicated a greater FN aBMD in ART-N and lower TH aBMD in ART-Y than Nref (Supplementary Table 1 ). Between baseline and 12 months, LS and WBLH aBMD decreased significantly in ART-Y, on average by 2.9% and 1.5% respectively, but not in Nref and ART-N (Figure 2 , Supplementary Table 2 ). By 12 months there was no significant change in TH aBMD in ART-Y, but there were marked increases in Nref and ART-N (Figure 2 , Supplementary Tables 1-3 ). ART-Y were lighter at baseline, with lower BMI, fat mass, lean mass, fat:lean 2 , hip and waist circumferences and higher waist:hip ratio than Nref and ART-N. By 12 months, their body weight, BMI and several other anthropometric variables had increased but remained lower than both Nref and ART-N ( Supplementary Table 1, Figure 2 ). Significant group-by-timepoint interaction terms in the 3-timepoint model confirmed that the patterns of within-individual change over time differed between the groups (Supplementary Table 1 ).
Between 12 and 24 months (Table 1) , there were no significant changes in aBMD at any site except for the total hip, where an increase was observed in all groups. The lack of significant group-by-time interaction terms in the 2-timepoint model confirmed that the group dependent changes were confined to the first 12 months. However, the trends in Nref for increasing aBMD at the LS, TH and FN continued and by 24 months, the increases from baseline were significant (Figure 2, Supplementary Tables 1 and 3 ). In consequence, the differences between ART-Y and Nref at 24 months were increased such that ART-Y had lower LS, TH, FN and WBLH aBMD compared to Nref on average by 5.3%, 6.5%, 5.6%, and 2.6% respectively ( Table 2 ). In addition, on an individual basis, a greater proportion of women in ART-Y at 24 months had lower aBMD than at baseline by >0.03 g/cm 2 , most particularly at the lumbar spine (Nref = 1/39 (2.6%); ART-N = 3/28 (11%); ART-Y 22/43 (51%) p≤0.0001), the greatest loss occurring before 12 months.
Between 12 and 24 months ART-Y continued to gain weight, BMI and adiposity, as shown by increases in fat mass, fat:lean 2 ratio and hip circumference but there were few significant changes in anthropometry in Nref and ART-N (Table 1) . However, when considered over the 24 months of the study, Nref had also increased significantly in weight, BMI and adiposity compared to baseline but ART-N did not (Figure 1 , Supplementary Tables   1 and 3) . Size-adjustment, to make allowance for these group differences in change in weight and body composition on bone mineral density, generally diminished the magnitude and statistical significance of the aBMD differences in ART-Y and ART-N relative to Nref but did not alter the overall pattern (Supplementary Table 3 ) Table 3 presents the biochemistry data at 12 and 24 months. Figure 3 illustrates the percentage differences from Nref at baseline in each of the 3 groups for albumin, TALP, CRP and ferritin at 0, 12 months and 24 months; the full summary data including baseline values are in Supplementary Table 4 . At baseline, ART-Y had lower serum albumin and higher CRP and ferritin which improved after ART initiation, but serum phosphate and TmP/GFR were similar to Nref and ART-N. ART-initiation was associated with higher TALP, P1NP and β-CTX at 12 months which was sustained at 24 months. Serum albumin decreased over This article is protected by copyright. All rights reserved. The inclusion of a group with HIV who were ART-unexposed is novel and unlikely to be repeated in future studies given the moves towards earlier ART initiation [26] .
These data suggest that, in South African women, HIV-positivity has no measurable negative effects on bone mineral status over a 24-month period, unlike the conclusions reported in earlier studies [27, 28] . However, exposure to TDF-containing ART was associated with loss of bone mineral and increased bone turnover in the first 12 months that stabilized by 24 months, as in other populations studied [11, 12] but not all [14] . While the duration of HIV infection prior to participation in the study was unknown, the range of baseline CD4 counts at baseline across the two groups of PWH suggests that the women had been infected for different lengths of time. Baseline analysis did not reveal significant This article is protected by copyright. All rights reserved.
differences in aBMD between women with and without infection or between those with HIV with low and preserved CD4 counts. This suggests that the observed reductions in aBMD observed in ART-Y were related to ART-exposure and not primarily driven by the presence of HIV.
At 24 months aBMD in ART-Y was significantly lower than Nref at all sites by 2-7%, even after allowing for differences in weight and weight gain, with higher bone turnover indices (in our previous report we showed that the elevation in TALP in ART-Y at 12 months was matched by higher bone-specific alkaline phosphatase activity, indicating a bone origin rather than liver) [5] . There was no evidence of bone loss in ART-N over 24 months and the aBMD of these women, with HIV, a preserved CD4 count and ART-unexposed, remained comparable to Nref despite not experiencing the same increase in weight. These results suggest that the overall bone health of women with HIV may be vulnerable to ART-exposure, leading to subsequent increases in skeletal fragility [29] , particularly following the menopause transition [30, 31] . This is important as traditional fracture prediction tools may underestimate fracture risk in women with HIV and requires further research [32] .
Published data overwhelmingly support an association between ART-exposure and loss of bone mineral over 24 months [14, 15, 33] . That similar results are seen in individuals without HIV exposed to TDF as part of HIV pre-exposure prophylaxis (PrEP) regimens, and reversal of loss after TDF discontinuation, supports the hypothesis that bone changes are directly related to ART rather than factors associated with HIV infection [11, 18, 34, 35] .
Furthermore improvements in BMD after switching from TDF to Tenofovir Alafemamide Fumarate (TAF) implicate TDF as the main driver of bone loss [36] . However, whether this is a direct effect of TDF on the skeleton or one mediated via increases in PTH remains unclear. It might represent a catabolic window, as proposed by Overton et al, wherein a high bone turnover state with excess bone resorption, may be a central mechanism of ARTassociated bone loss [37] . Such potential mechanisms, their duration and ultimate skeletal consequences require further study.
Nref women and those with HIV who initiated ART gained weight rapidly at 12 months [5] and this continued to 24 months, due to an increase in fat mass rather than lean mass. No change in weight or body composition was seen in women with HIV not exposed to ART.
Rapid and sustained increases in adiposity are likely to be contributory to future cardiometabolic disease risk in women regardless of HIV status [38] [39] [40] . Those living with HIV may be at higher risk of such outcomes [41, 42] though the precise mechanisms are unknown. There is some evidence suggesting that South Africans with HIV receive enhanced levels of care for their obesity-related conditions compared to those without HIV [43] . This may, in part, explain the lack of weight gain in the ART-N group however, there are many unanswered questions concerning the overlapping epidemic of HIV and cardiometabolic disease in Africa [44] and how this interplay influences future fracture risk.
Unlike previous reports [45] [46] [47] we have no indication in this group of South African women that either HIV-infection or ART-exposure was associated with consistent differences in vitamin D status over time, although by 24 months ART-unexposed women had higher mean 25(OH)D than the other groups; indeed the HIV-negative reference group had the lowest mean concentration at 24 months. The mean 25(OH)D concentration in all 3 groups exceeded 50 nmol/l at all timepoints.
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The data presented in this longitudinal sub-set, demonstrating no significant groupdependent changes over time in serum phosphate and TmP/GFR, argue against perturbations in renal phosphate handling as the key mechanism to explain aBMD loss with ARTexposure. CRP and ferritin concentrations, both acute phase markers, were higher for ART-Y at baseline than for the other groups but not at 12 and 24 months. This likely represents improvements in inflammation associated with initially untreated advanced HIV infection
[48] which improved with immune restoration, though other mechanisms are possible [49] .
The strengths of the study were the longitudinal design, that no participant was exposed to ART at baseline, inclusion of an age-appropriate HIV-negative reference group, an ARTunexposed group and the fact that the majority of ART-Y received standard South African first-line treatment, thereby minimizing the confounding effects of various ART combinations. It is limited by several factors including: observational design, the restricted number of participants retained in the cohort to 24 months, absence of HIV-specific clinical data (e.g. HIV-viral load, duration of HIV-infection and adherence to ART), and the fact that not all women in the ART-Y group were exposed uniformly to ART, the median duration of exposure by 24 months was 685 [591, 742] days.
In summary, this study suggests that, in urban, black South African women, HIV-infection per se has no discernible negative effects on bone mineral status over a 24-month period but that exposure to TDF-based ART was associated with loss of bone mineral and an increase in bone turnover that largely stabilized by 24 months. While our data suggest that loss of aBMD plateaus after 12 months in these pre-menopausal women, and so provide some reassurance, they cannot predict whether there may be an exaggerated trajectory of menopausal bone loss or fracture risk. Prodrugs of TDF such as TAF have been repeatedly demonstrated to be more bone-sparing than TDF [33, 50] . However, it is unknown, at this stage, if this will affect future fracture risk [51] . TAF is not widely available in Africa and, for cost reasons, is unlikely to replace TDF for some time in the treatment and prevention of HIV or hepatitis B.
Since TDF is currently part of first-line ART in many, particularly low income, countries, there is a need for future research, with longer follow up, to determine the long-term skeletal effects of HIV-infection, ART-exposure and other lifestyle [10] factors in order to inform policies on osteoporosis and fracture prevention within an African context. This article is protected by copyright. All rights reserved.
Footnote to Table 1 Nref, n = 39, HIV-negative; ART-N, n = 28, people with HIV (PWH) not on ART 0-24m; ART-Y, n = 43; PWH on ART at 24 months who initiated prior to 12 months, WBLH = whole body less head. Data are means ± SDs, aBMD data are unadjusted. *Interaction p = significance of group-by-timepoint interaction term in the 2-timepoint model ( This article is protected by copyright. All rights reserved. This article is protected by copyright. All rights reserved. Table 3 Nref, n = 39, HIV-negative; ART-N, n = 28, people with HIV (PWH) not on ART 0-24m; ART-Y, n = 43; PWH on ART at 24 months who initiated prior to 12 months. Data are means ± SDs for normal distributions, for those with positive skew ( ¶) are median [25,75 percentile] . *Interaction p = significance of group-by-timepoint interaction term in the 2timepoint model (12/24 months). #Serum creatinine values, assayed using the Jaffe method, were corrected to provide traceability to the reference method using the compensation This article is protected by copyright. All rights reserved. Accepted Article
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